Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: 65 Years and older (Adult, Senior) Sexes Eligible for Study: Male Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria:
Fluid and electrolyte disturbances: Retention of sodium, chloride, water, potassium, calcium, and inorganic phosphates.
Gastrointestinal: Nausea, cholestatic jaundice, alterations in liver function tests, rarely hepatocellular neoplasms and peliosis hepatis (see WARNINGS ).
Hematologic: Suppression of clotting factors II, V, VII, and X, bleeding in patients on concomitant anticoagulant therapy, and polycythemia.
Nervous system: Increased or decreased libido, headache, anxiety, depression, and generalized paresthesia.
Allergic: Hypersensitivity, including skin manifestations and anaphylactoid reactions.
Vascular Disorders: venous thromboembolism
Miscellaneous: Inflammation and pain at the site of intramuscular injection.
Testosterone enanthate ( USAN , BAN ) (brand names Delatestryl , Testostroval , Testro LA , Andro LA , Durathate , Everone , Testrin , Andropository ), or testosterone heptanoate , is an androgen and anabolic steroid and a testosterone ester .    Along with testosterone cypionate and testosterone propionate , it is one of the most widely used testosterone esters.  Testosterone enanthate was first introduced in 1952.  Administered via intramuscular injection , it is the most widely used form of testosterone in androgen replacement therapy .